

1 **Association of polypharmacy and burden of comorbidities on COVID-19**
2 **adverse outcomes in people with type 1 or type 2 diabetes**

3 JK Gupta¹, R Ravindrarajah¹, George Tilston¹, W Ollier², DM Ashcroft^{3,4}, AH Heald^{5,6}

4 ¹ Division of Informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health,
5 University of Manchester, Manchester, UK.

6 ² Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, UK

7 ³ Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, Medicine and
8 Health, University of Manchester, Manchester, UK.

9 ⁴ NIHR Greater Manchester Patient Safety Research Collaboration (PSRC), University of Manchester,
10 UK

11 ⁵ Department of Diabetes and Endocrinology, Salford Royal NHS Foundation Trust, Salford, UK

12 ⁶ Faculty of Biology, Medicine and Health, Manchester, UK

13

14 **RUNNING TITLE:** Polypharmacy and comorbidity impact on COVID-19 health outcome in diabetes

15

16 **Abstract**

17 Aim: To investigate whether polypharmacy and comorbidities conveyed more risk of adverse health
18 outcomes following COVID-19 infection in people with type 1 diabetes (T1DM) or type 2 diabetes
19 (T2DM).

20 Materials and methods: The Greater Manchester Care Record (GMCR) is an integrated database of
21 electronic health records containing data collected from 433 general practices in Greater Manchester.
22 Baseline demographic information (age, BMI, gender, ethnicity, smoking status, deprivation index),
23 hospital admission or death within 28 days of infection were extracted for adults (18+) diagnosed with
24 either T1DM or T2DM.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 Results: For T2DM, 16 to 20 medications ($p=0.01$; OR [95% CI]=2.37 [1.31 to 4.32]) and > 20
26 medications ($p=0$; OR [95% CI]=3.14 [1.75 to 5.62]) were associated with increased risk of death
27 following COVID-19 infection. Increased risk of hospital admissions in T2DM individuals was
28 determined for 11 to 15 medications ($p=0.01$; OR [95% CI]=1.34 [1.06 to 1.69]) and above. This was
29 independent of comorbidities, metabolic and demographic factors. For T1DM there was no
30 association of polypharmacy with hospital admission. Respiratory, cardiovascular/cerebrovascular
31 and gastrointestinal conditions were associated with increased risk of hospital admissions and deaths
32 in T2DM ($p>0.001$).

33 Conclusion: We have shown in T2DM an independent association of number of medications taken
34 from 11 upwards with adverse health consequences following COVID-19 infection. We also found that
35 individuals with diabetes develop comorbidities that were common across both T1DM and T2DM. This
36 study has laid the foundation for future investigations into the way that complex pharmacological
37 interactions may influence clinical outcomes in people with T2DM.

38

39 **Keywords:** polypharmacy; comorbidity; electronic health records; COVID-19

40

41 Introduction

42 Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) or COVID-19 is the pathogenic coronavirus
43 that led to the 2020 pandemic. COVID-19 infections can lead to adverse outcomes, such as hospital
44 admission or death, the risk of which are increased further for individuals diagnosed with either type
45 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) ^{1,2}. Increased risk of adverse health
46 outcomes following COVID-19 infection have also been linked to other underlying medical conditions,
47 which has raised concerns for chronic disease care ³⁻⁷. It has been showed that socially marginalised
48 and psychiatrically vulnerable individuals are at higher risk of severe health outcomes following
49 COVID-19 infection ⁸. McQueenie et al. (2020) investigated the UK Biobank data to determine the
50 association between multi-morbidity (including polypharmacy as a proxy) and COVID-19 infection risk

51 ⁹. McQueenie et al. (2020) reported that individuals diagnosed with ≥ 2 cardiometabolic conditions and
52 increasing polypharmacy were associated with increased the risk of COVID-19 infection ⁹.
53 Previous studies of COVID-19 in individuals with T1DM and T2DM (in the Greater Manchester (GM)
54 area) have shown that the prescribing of certain medications influenced the likelihood of
55 hospitalisation or death following COVID-19 infection ^{10,11}. Many individuals in this population are
56 often prescribed, and are taking, multiple medications as they live with other long-term conditions.
57 The definition of ‘polypharmacy’ has been shown to widely vary in the published literature ¹². In
58 addition to this term, Masnoon et al. (2017) summarised that the terms minor, moderate and major
59 polypharmacy were used in literature to describe when between 2 to 11 or more medications are
60 consumed. The most commonly reported number of medications across these ‘polypharmacy’ terms
61 was greater than or equal to 5, as identified in the review ¹².
62 It is widely accepted that the higher the number of medications prescribed and taken by an individual,
63 the higher the risk of poor health outcomes. Recent reviews have reported a high prevalence of
64 polypharmacy in older people diagnosed with diabetes and an association with several health-related
65 outcomes, including falls, syncope, hospitalization, and death, as well as highlighting the need to
66 reduce inappropriate prescribing ^{13–15}. Several studies have also investigated the relationship between
67 polypharmacy and severe COVID-19 health outcomes ^{16,17}. However, there is little understanding of
68 how polypharmacy in people with diabetes might affect their risk of severe health outcome post
69 COVID-19 infection, other than the public health burden and impact of adverse drug-drug interactions
70 in individuals ¹⁸.
71 Electronic health records (EHR) emerged as a useful tool for public health and COVID-19 research, as
72 described by Madhavan et al. (2021) and Casey et al. (2016) ^{19,20}. It is also useful for improving health
73 service for example by identifying and understanding health inequalities ^{21,22}.
74 To date, there are no studies that explore the associations between both polypharmacy and
75 comorbidity with adverse health outcomes, such as hospital admission or death, post first infection of
76 COVID-19 specifically in individuals with diabetes. This study aimed to investigate whether

77 polypharmacy and comorbidities conveys more risk of adverse outcomes in people with diabetes
78 when testing positive for COVID-19 infection in UK EHR data.

79

80 **Materials and methods**

81 **Cohort data source**

82 The Greater Manchester Care Record (GMCR) is an integrated database of primary care, secondary
83 care and mental health trusts from across GM ([https://gmwearebettertogether.com/research-and-](https://gmwearebettertogether.com/research-and-planning/)
84 [planning/](https://gmwearebettertogether.com/research-and-planning/)) for retrospective analyses covering a population of approximately 3 million people. Health
85 and care data were collected from 433 of 435 (99.5%) general practices in GM. Data were de-identified
86 at source and were extracted from the GMCR database. The inclusion criteria for this study were
87 defined as individuals that are registered with a GM GP practice and with a diagnosis of T1DM or T2DM
88 and age 18 or above. Individuals with a positive test for COVID-19 close to January 2020 were included
89 in this study. **Variables and data cleaning**

90 Baseline demographic information (age, BMI, gender, ethnicity, smoking status, deprivation index),
91 hospital admission or death within 28 days of infection were extracted for adults (18+) diagnosed with
92 either T1DM or T2DM (the codes applied are summarised in Appendix 1). Other rare forms of diabetes
93 were not included.

94 Hospital admissions were recorded within 4 weeks after, or 2 weeks before a positive COVID-19 test
95 (between Jan 2020 to May 2022). The exposure was defined as prescribed medications, which were
96 recorded in the EHRs and mapped to the corresponding BNF (British National Formulary) chapters.
97 For this study, medications were considered at a single point in time, the month closest to first COVID-
98 19 infection date (January 2020 onwards). The BNF groups were not mutually exclusive, therefore
99 medications that are grouped under more than one chapter were counted. History of comorbidity was
100 collected before March 2020.

101 Individuals who were not assigned a gender were excluded. A total of 410 individuals having a code
102 for both T1DM and T2DM were excluded. Data were checked for extreme outliers or inconsistent
103 values and removed as appropriate.

104 **Ethics**

105 This project was reviewed, and ethical approval for COVID-19 research was overseen by Health
106 Innovation Manchester and granted by the Greater Manchester Care Record (GMCR) review board
107 (ref: IDCR-RQ-046). This research was performed with anonymised data, in line with the Health
108 Research Authority's Governance arrangements for research ethics committees.

109 **Statistical methods**

110 Multivariable logistic regression analyses were performed on the T1DM and T2DM individuals,
111 measuring exposure to number of medications and comorbidities, with either hospital admission or
112 death after COVID-19 infection (within 28 days of COVID-19 diagnosis) as the outcome. The models
113 were adjusted for age, BMI, ethnicity, smoking status, IMD, eGFR < 60, cholesterol, HBA1C and blood
114 pressure. Analyses were performed in STATA v17.

115 This manuscript follows the reporting recommendation of RECORD-PE ²³.

116

117 **Results**

118 The study cohort included patients diagnosed as T1DM and T2DM separately. Across the Greater
119 Manchester Region a total of 145,907 individuals were diagnosed with T2DM and 9,705 were
120 diagnosed with T1DM (Table 1; Table 2). The number of deaths in T1DM were too low (n=30) for
121 further statistical analyses to explore the association with mortality.

122

123 **Table 1. Baseline demographics of individual diagnosed with Type 1 diabetes (T1DM) or Type 2**
124 **diabetes (T2DM).**

	Type 1 Diabetes	Type 2 Diabetes
	<i>N=9,705</i>	<i>N=145,907</i>
Age (years)	47.3±16.8	65.8±13.8
BMI (kg/m ²)	27.7±7.0	31.0±7.7

Gender:		
Female	4143 (42.7)	65922 (45.2)
Male	5562 (57.3)	79985 (54.8)
Smoking status:		
Non-smoker	3967 (40.9)	51823 (35.5)
Current smoker	1804 (18.6)	20906 (14.3)
Ex-smoker	3765 (38.8)	71519 (49.0)
Unknown/missing	169 (1.7)	1659 (1.1)
Ethnicity:		
White	8020 (82.6)	102051 (69.9)
Asian	565 (5.8)	25359 (17.4)
Black	221 (2.3)	5176 (3.6)
Mixed	107 (1.1)	1528 (1.1)
Other	379 (3.9)	6184 (4.2)
Missing/refused	413 (4.3)	5609 (3.8)
Deprivation index/Townsend quintile (IMD)		
1 (least deprived)	1182 (12.2)	13471 (9.2)
2	1451 (15.0)	19080 (13.1)
3	1395 (14.4)	18017 (12.4)
4	1984 (20.4)	28863 (19.8)
5 (most deprived)	3680 (37.9)	66426 (45.5)
Missing	13 (0.1)	50 (0.03)
Total number of medications prescribed*		
0	543 (5.60)	13359 (9.16)
1 to 5	5822 (59.99)	51999 (35.64)
6 to 10	1879 (19.36)	38533 (26.41)
11 to 15	744 (7.67)	21433 (14.69)
16 to 20	348 (3.59)	9880 (6.77)
> 20	369 (3.80)	10703 (7.34)
Systolic blood pressure (mm Hg) †	127.1±15.2	131.1±14.5
Diastolic blood pressure (mm Hg) †	74.8±9.8	75.9±9.6
HBA1C (mmol/mol) †	69.3±20.3	56.8±17.0
eGFR (mL/min/1.73 m²) < 60 ‡	907 (9.4)	25851 (17.7)
eGFR (mL/min/1.73 m ²) †	81.0±15.5	75.4±17.2
Cholesterol (mmol/mol) †	4.5±1.1	4.3±1.1
LDL (mmol/L) †	2.4±0.9	2.2±0.9
HDL (mmol/L) †	1.5±0.5	1.2±0.4
Diabetes duration (years)	20.6±14.3	10.4±7.45
Vaccination status: (define prior to/around the time of first infection)		
Yes	8816 (90.8)	135141 (92.6)
No	889 (9.2)	10766 (7.4)
Prescribed medications: *		
Metformin	1015 (10.5)	72084 (49.4)
SGLT2 *	163 (1.7)	16134 (11.1)
Insulin	6854 (70.6)	12149 (8.3)
Arb/ACE inhibitors	1759 (18.1)	44127 (30.2)
Antiplatelet (clopidogrel/aspirin)	1177 (12.1)	31403 (21.5)
Angiotensin receptor blockers	710 (7.3)	20168 (13.8)
Sulphonylureas	98 (1.0)	22011 (15.1)

GLP1 receptor agonists	79 (0.8)	4475 (3.1)
Alogliptin	36 (0.4)	10196 (7.0)
Linagliptin	37 (0.4)	5388 (3.7)
Saxagliptin	< 10 (0)	944 (0.7)
Sitagliptin	29 (0.3)	6570 (4.5)
Vildagliptin	< 10 (0)	396 (0.27)
Admission to hospital (within 28 days of infection)	146(1.5)	2107 (1.4)
Length of stay in hospital (days)	4.5±8.3	7.1±11.9
Deaths (within 28 days of confirmed infection)	30 (0.3)	885 (0.6)

125 Categorical variables presented as N (%) and continuous variables as mean (±SD)

126 Townsend index: 1 denotes the least deprived and 5 the most deprived.

127 * Medications prescribed close to January 2020.

128 † Closest point before first COVID-19 +ve test

129 ‡ Estimated glomerular filtration rate

130 * Sodium glucose co-transporter 2 inhibitor (SGLT2i) or a glucagon-like peptide 1 (GLP-1) agonist.

131

132 A varying number of multiple medications were prescribed to individuals with T1DM or T2DM (Table
133 1). A large proportion of individuals were prescribed between 1 to 5 medications; the distribution of
134 number of medications prescribed and BNF chapters can be seen in Figure S1 and Figure S2. In T2DM,
135 after endocrine and cardiovascular medications, the largest number of multiple prescriptions were
136 from the gastrointestinal (GI) BNF chapter.

137 Common comorbidities were grouped into broader categories (see Supplementary Information Table
138 S1) and counts were collated for T1DM and T2DM. The top six modal comorbidity groups identified in
139 T2DM were mental health conditions, hypertension, gastrointestinal or liver disease, pain, respiratory
140 conditions (or sinus-related) and cardiovascular/cerebrovascular conditions (Table 2). Of the
141 individuals diagnosed with T2DM, 69.9% were diagnosed with hypertension and 44.9% with mental
142 health conditions (Table 2). The same six comorbidity groups were also identified in the individuals
143 with T1DM (Table S2).

144

145 **Table 2. Prevalence of co-morbidity groups in individuals diagnosed with T2DM. The top 6 groups**
146 **are shown in italics.**

Morbidity group	N	%
<i>Hypertension</i>	101995	69.9
<i>GI/liver disease</i>	82193	56.3
<i>Mental health disorder</i>	65487	44.9
<i>Pain</i>	60237	41.3
<i>Cardiovascular/cerebrovascular</i>	48213	33.0

<i>Respiratory/sinus</i>	41653	28.6
Sensory	34541	23.7
Skin/connective tissue disorder	28459	19.5
Chronic kidney disease	27931	19.1
Neurological disorders	22795	15.6
Thyroid disorders	14476	9.9
Prostate diseases	9276	6.4
Alcohol substance abuse	9108	6.2
Cancer	7892	5.4
Dementia	6498	4.5
Glaucoma	6262	4.3
Learning disability	1016	0.7

147

148 **Logistic Regression Analysis**

149 Odds ratios (95% confidence intervals) of the univariate regression are reported in the individuals with
150 T1DM and T2DM respectively.

151 **T1DM**

152 An increased risk of adverse outcomes post-infection was observed for individuals with T1DM and
153 GI/liver disorders ($p=0$; 3.45 [2.12 to 5.62]) and pain associated conditions ($p=0.04$; OR [95% CI] = 1.56
154 [1.02 to 2.37]) (Table 3). Age was significant. Other significant variables included eGFR < 60 ($p=0$; OR
155 [95% CI] = 2.79 [1.75 to 4.47]). There was no association with polypharmacy.

156

157 **Table 3. Logistic regression analyses of hospital admission resulting from COVID-19 infection in**
158 **individuals with T1DM.**

Variable	OR (95% CI)	p value
Age	0.96 (0.95 to 0.98)	> 0.001
Gender		
Females		
Males	0.79 (0.54 to 1.17)	0.24
BMI	0.99 (0.96 to 1.02)	0.49
Ethnicity		
White		
Asian	0.92 (0.43 to 1.96)	0.83
Black	0.39 (0.05 to 2.88)	0.36
Mixed	1.89 (0.44 to 8.04)	0.39
Other	0.45 (0.11 to 1.85)	0.27
Unknown	0.25 (0.03 to 1.81)	0.17
Smoking status		
Non-smoker		
Current smoker	0.86 (0.49 to 1.51)	0.59
Ex-smoker	1.02 (0.66 to 1.57)	0.92
Unknown/missing	1.24 (0.29 to 5.36)	0.78

IMD		
1 (least deprived)		
2	0.86 (0.4 to 1.85)	0.71
3	0.65 (0.29 to 1.45)	0.29
4	1 (0.5 to 1.99)	1
5 (most deprived)	0.84 (0.44 to 1.61)	0.60
Missing		
eGFR<60	2.79 (1.75 to 4.47)	> 0.001
Cholesterol	0.92 (0.78 to 1.1)	0.37
HBA1C	1 (0.99 to 1.01)	0.68
Systolic BP	1 (0.98 to 1.01)	0.79
Diastolic BP	1.02 (1 to 1.04)	0.11
Mental health disorder	0.69 (0.46 to 1.03)	0.07
Hypertension	1.18 (0.75 to 1.86)	0.48
GI/liver disorder	3.45 (2.12 to 5.62)	> 0.001
Pain	1.56 (1.02 to 2.37)	0.04
Respiratory/sinus conditions	0.99 (0.65 to 1.5)	0.95
Cardiovascular/cerebrovascular	1.33 (0.81 to 2.16)	0.26
Total number of medications:		
0		
1 to 5	1 (0.23 to 4.27)	1
6 to 10	2.14 (0.49 to 9.38)	0.31
11 to 15	2.5 (0.54 to 11.55)	0.24
16 to 20	3.58 (0.74 to 17.33)	0.11
> 20	2.16 (0.42 to 10.99)	0.36

159

160 T2DM

161 In individuals with T2DM, an increased number of medications, from 11 upwards was associated with
 162 increased risk of hospital admission following COVID-19 infection (Table 4). Individuals diagnosed with
 163 co-morbidities in the following morbidity groups had an increased likelihood of hospital admission:
 164 mental health disorders (p=0; OR [95% CI] = 1.17 (1.05 to 1.29)); Gastro-intestinal/liver disorders (p=0;
 165 OR [95% CI] = 1.98 (1.74 to 2.25)); pain (p=0; OR [95% CI] = 1.41 (1.27 to 1.56)); respiratory/sinus
 166 conditions (p=0; OR [95% CI] = 1.24 (1.11 to 1.37)) and cardiovascular/cerebrovascular conditions
 167 p=0; OR [95% CI] = 1.44 (1.29 to 1.61)). People with T2DM and eGFR level <60 (p= 0; OR [95% CI] =
 168 1.43 [1.27 to 1.61]) also had an increased risk of hospital admission, similarly HBA1C levels (p= 0.01;
 169 OR [95% CI] = 1 [1 to 1.01]) were also at increased risk (Table 4).

170 Males were more likely to be admitted to hospital after infection with COVID-19 (p=0; OR [95% CI] =
 171 1.31 [1.18 to 1.46]). Extremes of BMI (too high or too low) was associated with a higher likelihood of
 172 adverse outcomes (hospitalisation & mortality) from COVID-19 (p=0; OR [95% CI] = 1.01 [1 to 1.02]).
 173 Age was protective of hospital admission; however the odds ratio was only slightly less than 1 (p=0.01;

174 OR [95% CI] = 0.99 [0.99 to 1]). Individuals of Asian (p=0.01; OR [95% CI] = 1.21 [1.06 to 1.39]) or Black
175 (p=0; OR [95% CI] = 1.44 [1.13 to 1.84]) ethnicities were also more likely to be admitted to hospital
176 following infection (Table 4).

177 Individuals who identified as ‘current smokers’ were not identified as being at increased risk (p=0; OR
178 [95% CI] = 0.51 [0.42 to 0.61]). However, individuals who lived in more deprived regions were
179 statistically significant IMD 4 and 5 (p=0.02; OR [95% CI] = 1.28 [1.04 to 1.57]; p=0.03; OR [95% CI] =
180 1.24 [1.02 to 1.5]) (Table 4).

181

182 **Table 4. Logistic regression analyses of hospital admission resulting from COVID-19 infection in**
183 **individuals with T2DM.**

Variable	OR (95% CI)	p value
Age	0.99 (0.99 to 1)	0.01
Gender		
Females		
Males	1.31 (1.18 to 1.46)	> 0.001
BMI	1.01 (1 to 1.02)	> 0.001
Ethnicity		
White		
Asian	1.21 (1.06 to 1.39)	0.01
Black	1.44 (1.13 to 1.84)	> 0.001
Mixed	1.06 (0.63 to 1.77)	0.83
Other	0.96 (0.74 to 1.24)	0.75
Unknown	0.95 (0.7 to 1.28)	0.73
Smoking status		
Non-smoker		
Current smoker	0.51 (0.42 to 0.61)	> 0.001
Ex- smoker	1 (0.89 to 1.12)	0.98
Unknown/missing	0.86 (0.53 to 1.4)	0.53
IMD		
1 (least deprived)		
2	1.07 (0.85 to 1.34)	0.56
3	1.09 (0.87 to 1.37)	0.45
4	1.28 (1.04 to 1.57)	0.02
5 (most deprived)	1.24 (1.02 to 1.5)	0.03
Missing		
eGFR<60	1.43 (1.27 to 1.61)	> 0.001
Cholesterol	1.02 (0.98 to 1.07)	0.37
HBA1C	1 (1 to 1.01)	0.01
Systolic BP	1 (1 to 1)	0.71
Diastolic BP	1 (1 to 1.01)	0.47
Mental health disorder	1.17 (1.05 to 1.29)	> 0.001
Hypertension	1.07 (0.95 to 1.22)	0.27
GI/liver disorder	1.98 (1.74 to 2.25)	> 0.001
Pain	1.41 (1.27 to 1.56)	> 0.001
Respiratory/sinus conditions	1.24 (1.11 to 1.37)	> 0.001

Cardiovascular/cerebrovascular	1.44 (1.29 to 1.61)	> 0.001
Total number of medications:		
0		
1 to 5	1.12 (0.9 to 1.4)	0.3
6 to 10	1.11 (0.89 to 1.39)	0.37
11 to 15	1.34 (1.06 to 1.69)	0.01
16 to 20	1.45 (1.12 to 1.87)	> 0.001
> 20	1.53 (1.19 to 1.97)	> 0.001

184

185 In individuals with T2DM, the number of deaths was 885 (0.6% of the total number of individuals
186 diagnosed with T2DM) (Table 1). An increased number of medications, from 16 to 20 to > 20 was
187 associated with increased risk of death following COVID-19 infection (p=0.01; OR [95% CI] = 2.37 [1.31
188 to 4.32] and p=0; OR [95% CI] = 3.14 [1.75 to 5.62] respectively) (Table 5).

189 People diagnosed with the following long-term conditions were at higher risk of death post-infection:
190 mental health disorders (p=0; OR [95% CI] = 1.54 (1.22 to 1.95)); respiratory/sinus conditions (p=0; OR
191 [95% CI] = 1.57 [1.24 to 1.99]) or cardiovascular/cerebrovascular conditions (p=0; OR [95% CI] = 1.69
192 [1.3 to 2.2]). A protective effect was observed for individuals living with GI/liver disorder (p=0; OR
193 [95% CI] = 0.52 (0.4 to 0.67)) or pain (p=0; OR [95% CI] = 0.51 [0.4 to 0.66]) (Table 5).

194 As with hospital admission, the risk of death in males and with increased BMI was high (p=0.02; OR
195 [95% CI] = 1.35 [1.05 to 1.73] and p=0; OR [95% CI] = 1.02 [1.01 to 1.04] respectively). Age was
196 associated with an increased risk of mortality post COVID-19 infection (p=0; OR [95% CI] = 1.09 [1.08
197 to 1.11]) (Table 5).

198 Individuals with T2DM and living in the most deprived regions (IMD 5) were at higher risk of death
199 following COVID-19 infection (p=0.02; OR [95% CI] = 1.68 [1.08 to 2.62]) or if their eGFR level measure
200 was <60 (p=0.01; OR [95% CI] = 1.38 [1.08 to 1.77]) (Table 5).

201

202 **Table 5. Logistic regression analyses of deaths resulting from COVID-19 infection in individuals**
203 **with T2DM.**

Variable	OR (95% CI)	p value
Age	1.09 (1.08 to 1.11)	> 0.001
Gender		
Females		
Males	1.35 (1.05 to 1.73)	0.02
BMI	1.02 (1.01 to 1.04)	> 0.001

Ethnicity		
White		
Asian	0.72 (0.46 to 1.12)	0.15
Black	0.67 (0.27 to 1.63)	0.37
Mixed	1.42 (0.45 to 4.5)	0.55
Other	0.7 (0.36 to 1.36)	0.29
Unknown	1.26 (0.72 to 2.21)	0.42
Smoking status		
Non-smoker		
Current smoker	1.02 (0.67 to 1.55)	0.95
Ex- smoker	0.94 (0.72 to 1.23)	0.68
Unknown/missing		
IMD		
1 (least deprived)		
2	1.44 (0.88 to 2.37)	0.15
3	1.18 (0.7 to 1.99)	0.53
4	1.48 (0.92 to 2.38)	0.11
5 (most deprived)	1.68 (1.08 to 2.62)	0.02
Missing		
eGFR<60	1.38 (1.08 to 1.77)	0.01
Cholesterol	1.08 (0.97 to 1.21)	0.15
HBA1C	1 (0.99 to 1.01)	0.97
Systolic BP	0.99 (0.98 to 1)	0.12
Diastolic BP	1 (0.99 to 1.01)	0.91
Mental health disorder	1.54 (1.22 to 1.95)	> 0.001
Hypertension	0.79 (0.57 to 1.1)	0.16
GI/liver disorder	0.52 (0.4 to 0.67)	> 0.001
Pain	0.51 (0.4 to 0.66)	> 0.001
Respiratory/sinus conditions	1.57 (1.24 to 1.99)	> 0.001
Cardiovascular/cerebrovascular	1.69 (1.3 to 2.2)	> 0.001
Total number of medications:		
0		
1 to 5	0.58 (0.32 to 1.06)	0.08
6 to 10	0.94 (0.54 to 1.67)	0.84
11 to 15	1.43 (0.8 to 2.55)	0.23
16 to 20	2.37 (1.31 to 4.32)	0.01
> 20	3.14 (1.75 to 5.62)	> 0.001

204

205 Discussion

206 We found that the number of medications prescribed to an individual was associated with an
 207 increased risk of severe outcome from COVID-19 infection, particularly in people living with T2DM
 208 (Table 4; Table 5). Given the large proportion of individuals diagnosed with comorbidities, it was not
 209 unexpected that many of these individuals were prescribed multiple medications (Figure S1; Figure
 210 S2). However, the effect of multiple medications was independent of the presence of the most
 211 common comorbidities. This study uniquely explored the relationship between number of
 212 medications and adverse outcome from COVID-19 infection in individuals diagnosed with diabetes in

213 the Greater Manchester population and is therefore distinct from our previous published studies in
214 this area ^{10,11}. We saw that polypharmacy, independent of other factors including major
215 multimorbidity, was associated with an increased likelihood of hospital admission in people with
216 T1DM and of hospitalisation and death in T2DM following COVID-19 infection. This has not been
217 specifically reported previously, although it was described in older individuals ²⁴. This is of relevance
218 to the consequences following any serious viral infection in people with diabetes, while also
219 highlighting the importance of regular medicine reviews in everyone with diabetes, where there may
220 be an opportunity to reduce the prescribed medications ²⁵.

221 The mean ages of individuals diagnosed with T1DM or T2DM are similar to the mean ages of a Swedish
222 cohort investigated by ¹. In our study we also identified several co-morbidities that increased the risk
223 of adverse health outcome post COVID-19 infection. Similar co-morbidities were identified for both
224 individuals with T1DM and T2DM. The increase in medications could be related to the co-morbidities
225 that these individuals are diagnosed with and receiving medications for. The impact of this on an
226 individual's risk of suffering from severe health outcome post COVID-19 infection warrants further
227 investigation. Notably, we also identified that there were a large proportion of diagnoses of mental
228 health conditions in people with T2DM (Table 2), though the highest number of diagnoses was
229 observed in people with T1DM (Table S2). The relationship between physical health conditions and
230 poor mental health is an area that is not fully understood, in addition to this, the impact of
231 polypharmacy is unknown.

232 Over-prescribing is an issue in the current healthcare system. Medication is routinely recorded,
233 therefore in clinical practice there is the potential to flag the number of medications prescribed to
234 clinicians to monitor. Thereby the number of prescriptions given to vulnerable individuals could be
235 limited as appropriate and effective for the individual, though this does require both routine
236 monitoring and structured reviews of the medications that people are taking. The UK healthcare
237 system looks to improve the management of prescriptions, and the removal of unnecessary
238 medications is key to reducing the burden of polypharmacy ^{26,27}.

239 One of the limitations of this study is that a measure of 'frailty' was not included²⁸. However, a count
240 of comorbidities is included which could possibly be used as a proxy for frailty. As the data from this
241 study originated from electronic health records, it is also subject to the limitations of how information
242 is coded when originally entered into the systems, such as missing data. Only 70% of individuals with
243 T1DM were recorded with a prescription of insulin (Table 1), this could be due to lack of recording or
244 unclear diagnosis, which highlights another issue with routinely collected data. Another issue is that
245 medications are recorded in the health care records are not true reflections of medications that are
246 concordant with the choices of the individual²⁹. A study in America demonstrated that EHR-related
247 medication errors can occur at different stages including at ordering, preparation, dispensing,
248 administering or monitoring stage, these can ultimately affect the data in EHRs³⁰. Inaccuracies of
249 coding are inherent in any project that relies on primary coded data. Nevertheless, the large number
250 of people included in the study means that such inaccuracies are unlikely materially to influence the
251 results. Furthermore, medications can also be counted in more than one BNF chapter, making it
252 difficult to determine unique counts. As this data was from one region in the UK, it is difficult to
253 generalise to the rest of the population.

254 Future work would include investigating the modal medications prescribed in this cohort and explore
255 possible drug-drug interactions between medications that could contribute to increasing the risk of
256 adverse outcome post COVID-19 infection. The burden of mental health conditions on people with
257 diabetes and how to effectively manage multiple long-term conditions, could also be explored. The
258 knowledge gained would be useful for future pandemics and better prepare our healthcare system.

259 In conclusion, we have identified that multiple medications were prescribed to many people living
260 with diabetes and that this was associated with a higher risk of adverse health outcome following
261 COVID-19 infection. We also found that individuals with diabetes also developed comorbidities that
262 were common across both Type 1 and 2 diabetes. Our analysis confirmed the impact of higher levels
263 of deprivation on increasing a person's a risk of adverse outcome post COVID-19 infection. This study

264 has laid the foundation for future investigations into the increased and complex treatments people
265 living with diabetes who develop other clinical complications.

266

267 Acknowledgements

268 This work was supported by the Turing-Manchester Feasibility Project Funding. The authors recognise
269 the Greater Manchester Care Record (a partnership of Greater Manchester Health and Social Care
270 Partnership, Health Innovation Manchester and Graphnet Health, on behalf of Greater Manchester
271 localities) in the provision of data required to undertake this work. This work uses data provided by
272 patients and collected by the NHS as part of their care and support. GT was funded by the NIHR
273 Manchester Biomedical Research Centre (NIHR203308) for this work. DMA is supported by the NIHR
274 Greater Manchester Patient Safety Research Collaboration (PSRC). The views expressed are those of
275 the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

276 Author contributions

277 RR performed the data cleaning and data analyses. JG, WO and AHH conceived the study. JG prepared
278 the figures and the manuscript. GT extracted the original dataset. DM WO and AHH contributed to all
279 sections of the paper and DM provided expert input from a pharmacological perspective. All authors
280 were involved in designing the study, interpreting results and the reviewing and editing of the
281 manuscript.

282 Conflicts of interest

283 Authors declare no conflict of interest.

284 Data availability statement

285 The datasets generated during and analysed during the current study are not publicly available as all
286 data access is subject to review by Health Innovation Manchester.

287 References

- 288 1. Rawshani A, Kjölhede EA, Rawshani A, et al. Severe COVID-19 in people with type 1 and type 2
289 diabetes in Sweden: A nationwide retrospective cohort study. *The Lancet Regional Health -*
290 *Europe*. 2021;4:100105. doi:10.1016/j.lanepe.2021.100105
- 291 2. Izzi-Engbeaya C, Distaso W, Amin A, et al. Adverse outcomes in COVID-19 and diabetes: a
292 retrospective cohort study from three London teaching hospitals. *BMJ Open Diabetes Res Care*.
293 2021;9(1):e001858. doi:10.1136/bmjdr-2020-001858
- 294 3. Kone AP, Martin L, Scharf D, et al. The impact of multimorbidity on severe COVID-19 outcomes
295 in community and congregate settings. *Dialogues in Health*. 2023;2:100128.
296 doi:10.1016/j.dialog.2023.100128
- 297 4. Li Y, Ashcroft T, Chung A, et al. Risk factors for poor outcomes in hospitalised COVID-19 patients:
298 A systematic review and meta-analysis. *J Glob Health*. 11:10001. doi:10.7189/jogh.11.10001
- 299 5. Fekadu G, Bekele F, Tolossa T, et al. Impact of COVID-19 pandemic on chronic diseases care
300 follow-up and current perspectives in low resource settings: a narrative review. *Int J Physiol*
301 *Pathophysiol Pharmacol*. 2021;13(3):86-93.
- 302 6. Danhieux K, Buffel V, Pairon A, et al. The impact of COVID-19 on chronic care according to
303 providers: a qualitative study among primary care practices in Belgium. *BMC Family Practice*.
304 2020;21(1):255. doi:10.1186/s12875-020-01326-3
- 305 7. Zheng Z, Peng F, Xu B, et al. Risk factors of critical & mortal COVID-19 cases: A systematic
306 literature review and meta-analysis. *Journal of Infection*. 2020;81(2):e16-e25.
307 doi:10.1016/j.jinf.2020.04.021
- 308 8. Nilsson SF, Laursen TM, Osler M, et al. Adverse SARS-CoV-2-associated outcomes among people
309 experiencing social marginalisation and psychiatric vulnerability: A population-based cohort
310 study among 4,4 million people. *The Lancet Regional Health - Europe*. 2022;20:100421.
311 doi:10.1016/j.lanepe.2022.100421
- 312 9. McQueenie R, Foster HME, Jani BD, et al. Multimorbidity, polypharmacy, and COVID-19 infection
313 within the UK Biobank cohort. *PLOS ONE*. 2020;15(8):e0238091.
314 doi:10.1371/journal.pone.0238091
- 315 10. Heald AH, Jenkins DA, Williams R, et al. The Risk Factors Potentially Influencing Hospital
316 Admission in People with Diabetes, Following SARS-CoV-2 Infection: A Population-Level Analysis.
317 *Diabetes Ther*. 2022;13(5):1007-1021. doi:10.1007/s13300-022-01230-2
- 318 11. Heald AH, Jenkins DA, Williams R, et al. Mortality in People with Type 2 Diabetes Following
319 SARS-CoV-2 Infection: A Population Level Analysis of Potential Risk Factors. *Diabetes Ther*.
320 2022;13(5):1037-1051. doi:10.1007/s13300-022-01259-3

- 321 12. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review
322 of definitions. *BMC Geriatr.* 2017;17(1):230. doi:10.1186/s12877-017-0621-2
- 323 13. Remelli F, Ceresini MG, Trevisan C, Noale M, Volpato S. Prevalence and impact of polypharmacy
324 in older patients with type 2 diabetes. *Aging Clin Exp Res.* 2022;34(9):1969-1983.
325 doi:10.1007/s40520-022-02165-1
- 326 14. Rochon PA, Petrovic M, Cherubini A, et al. Polypharmacy, inappropriate prescribing, and
327 deprescribing in older people: through a sex and gender lens. *The Lancet Healthy Longevity.*
328 2021;2(5):e290-e300. doi:10.1016/S2666-7568(21)00054-4
- 329 15. Bhagavathula AS, Vidyasagar K, Chhabra M, et al. Prevalence of Polypharmacy,
330 Hyperpolypharmacy and Potentially Inappropriate Medication Use in Older Adults in India: A
331 Systematic Review and Meta-Analysis. *Frontiers in Pharmacology.* 2021;12. Accessed August 11,
332 2023. <https://www.frontiersin.org/articles/10.3389/fphar.2021.685518>
- 333 16. McKeigue PM, Kennedy S, Weir A, et al. Relation of severe COVID-19 to polypharmacy and
334 prescribing of psychotropic drugs: the REACT-SCOT case-control study. *BMC Medicine.*
335 2021;19(1):51. doi:10.1186/s12916-021-01907-8
- 336 17. Iloanusi S, Mgbere O, Essien EJ. Polypharmacy among COVID-19 patients: A systematic review. *J*
337 *Am Pharm Assoc (2003).* 2021;61(5):e14-e25. doi:10.1016/j.japh.2021.05.006
- 338 18. Rahman S, Singh K, Dhingra S, et al. The Double Burden of the COVID-19 Pandemic and
339 Polypharmacy on Geriatric Population – Public Health Implications. *Ther Clin Risk Manag.*
340 2020;16:1007-1022. doi:10.2147/TCRM.S272908
- 341 19. Madhavan S, Bastarache L, Brown JS, et al. Use of electronic health records to support a public
342 health response to the COVID-19 pandemic in the United States: a perspective from 15
343 academic medical centers. *J Am Med Inform Assoc.* 2021;28(2):393-401.
344 doi:10.1093/jamia/ocaa287
- 345 20. Casey JA, Schwartz BS, Stewart WF, Adler NE. Using Electronic Health Records for Population
346 Health Research: A Review of Methods and Applications. *Annual Review of Public Health.*
347 2016;37(1):61-81. doi:10.1146/annurev-publhealth-032315-021353
- 348 21. Kruse CS, Stein A, Thomas H, Kaur H. The use of Electronic Health Records to Support Population
349 Health: A Systematic Review of the Literature. *J Med Syst.* 2018;42(11):214.
350 doi:10.1007/s10916-018-1075-6
- 351 22. Cowie MR, Blomster JI, Curtis LH, et al. Electronic health records to facilitate clinical research.
352 *Clin Res Cardiol.* 2017;106(1):1-9. doi:10.1007/s00392-016-1025-6
- 353 23. Langan SM, Schmidt SA, Wing K, et al. The reporting of studies conducted using observational
354 routinely collected health data statement for pharmacoepidemiology (RECORD-PE). *BMJ.*
355 Published online November 14, 2018:k3532. doi:10.1136/bmj.k3532
- 356 24. Rahman S, Singh K, Dhingra S, et al. The Double Burden of the COVID-19 Pandemic and
357 Polypharmacy on Geriatric Population – Public Health Implications. *Ther Clin Risk Manag.*
358 2020;16:1007-1022. doi:10.2147/TCRM.S272908
- 359 25. Kerr L. Polypharmacy in diabetes and solutions for greater adherence. *Practical Diabetes*
360 *International.* 2009;26(7):289-290. doi:10.1002/pdi.1402

- 361 26. The AHSN Network. Polypharmacy. The AHSN Network. Published 2022. Accessed April 7, 2023.
362 <https://www.ahsnnetwork.com/programmes/medicines/polypharmacy/>
- 363 27. Department of Health and Social Care. National overprescribing review report. GOV.UK.
364 Published 2023. Accessed April 7, 2023. [https://www.gov.uk/government/publications/national-](https://www.gov.uk/government/publications/national-overprescribing-review-report)
365 [overprescribing-review-report](https://www.gov.uk/government/publications/national-overprescribing-review-report)
- 366 28. Hanlon P, Nicholl BI, Jani BD, Lee D, McQueenie R, Mair FS. Frailty and pre-frailty in middle-aged
367 and older adults and its association with multimorbidity and mortality: a prospective analysis of
368 493 737 UK Biobank participants. *The Lancet Public Health*. 2018;3(7):e323-e332.
369 doi:10.1016/S2468-2667(18)30091-4
- 370 29. Marzec LN, Maddox TM. Medication Adherence in Patients with Diabetes and Dyslipidemia:
371 Associated Factors and Strategies for Improvement. *Curr Cardiol Rep*. 2013;15(11):418.
372 doi:10.1007/s11886-013-0418-7
- 373 30. Carayon P, Du S, Brown R, Cartmill R, Johnson M, Wetterneck TB. EHR-related medication errors
374 in two ICUs. *J Healthc Risk Manag*. 2017;36(3):6-15. doi:10.1002/jhrm.21259
- 375